Jayastu Senapati: Largest reported cohort in secondary AML
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X:
“Check out our manuscript just published in American Journal of Hematology on Treated Secondary-AML: 673 patients, largest reported cohort.
- High-risk subtype: outcomes dismal, even in rare patients with fav genomics.
- Warrants an independent prognostic designation.
- Ven improves outcomes in patients without TP53 mutation: med OS still <10 mos.
- AlloHSCT leads to superior outcomes: indicated in all patients with TS-AML, irrespective of genomics.”
Authors: Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, Nicholas J. Short, Gautam Borthakur, Rashmi Kanagal-Shamanna, Guilin Tang, Elias Jabbour, Courtney D. DiNardo, Naval Daver, Guillermo Montalban-Bravo, Vishrut Shah, Amin Alousi, Elizabeth Shpall, Uday Popat, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Jayastu Senapati, an Assistant Professor of Leukemia at MD Anderson Cancer Center, specializes in hematology. He has been honored with several awards, including the ASCO Conquer Cancer Merit Award in 2022 and 2023, and the ASH Abstract Achievement Award in 2023, among many others.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023